Product Description: Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576-3586.
CAS Number: 1826819-57-1
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody